Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06037577 | Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects | PHASE1 | COMPLETED | 8 | — | — | Mar 5, 2019 | May 5, 2019 | Sep 14, 2023 | 1 | Israel |
Incidence and characteristics of adverse events (AEs) occurring following single subcutaneous doses of CM-101
Maximum CM-101 plasma concentration (Cmax)
Time to Cmax (tmax)
Area under the curve (AUC) to the final concentration ≥ limit of quantitation (LOQ), AUC(0-t) and to infinity AUCinf
Terminal elimination rate constant (λz)
Terminal elimination half-life (T½)
| Arm | Type | Description |
|---|---|---|
| Anti-human CCL24 monoclonal antibody (CM-101) | EXPERIMENTAL | Single 5 mg/kg of CM-101, Subcutaneous administration |
| Placebo | PLACEBO_COMPARATOR | Placebo : Subcutaneous administration |
| Name | Type | Description |
|---|---|---|
| CM-101 | DRUG | Anti-human CCL24 monoclonal antibody (CM-101) |
| Placebo | DRUG | Placebo Comparator |
Inclusion Criteria: 1. Subjects must provide written informed consent prior to participating in the study. 2. Considered healthy by the Investigator as defined by no clinically relevant abnormalities identified by a detailed medical history, full physical examination, 12-lead ECG, and clinical labo...